| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Natriuretic Peptide, Brain | 172 | 2023 | 1723 | 22.760 |
Why?
|
| Heart Failure | 273 | 2024 | 11670 | 17.250 |
Why?
|
| Peptide Fragments | 142 | 2023 | 5112 | 13.780 |
Why?
|
| Troponin T | 52 | 2023 | 780 | 7.580 |
Why?
|
| Natriuretic Peptides | 30 | 2024 | 155 | 6.760 |
Why?
|
| Troponin I | 29 | 2022 | 651 | 6.420 |
Why?
|
| Troponin | 27 | 2024 | 502 | 5.710 |
Why?
|
| Stroke Volume | 77 | 2024 | 5496 | 5.520 |
Why?
|
| Dyspnea | 40 | 2020 | 1347 | 4.920 |
Why?
|
| Receptors, Cell Surface | 32 | 2015 | 2822 | 4.810 |
Why?
|
| Myocardial Infarction | 64 | 2024 | 11461 | 4.420 |
Why?
|
| Acute Coronary Syndrome | 33 | 2024 | 2190 | 3.820 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 8 | 2020 | 208 | 3.530 |
Why?
|
| Ventricular Dysfunction, Left | 26 | 2024 | 2118 | 3.510 |
Why?
|
| Ventricular Remodeling | 18 | 2024 | 1267 | 3.430 |
Why?
|
| Galectin 3 | 12 | 2016 | 240 | 3.180 |
Why?
|
| Chest Pain | 16 | 2022 | 1091 | 3.170 |
Why?
|
| Prognosis | 155 | 2024 | 29629 | 3.030 |
Why?
|
| Cardiovascular Diseases | 49 | 2024 | 15501 | 3.010 |
Why?
|
| Diabetic Cardiomyopathies | 5 | 2024 | 90 | 2.800 |
Why?
|
| Protein Precursors | 27 | 2018 | 1132 | 2.710 |
Why?
|
| Heart Failure, Systolic | 9 | 2021 | 135 | 2.640 |
Why?
|
| Coronary Angiography | 25 | 2024 | 4471 | 2.610 |
Why?
|
| Biphenyl Compounds | 12 | 2023 | 1007 | 2.310 |
Why?
|
| Angiotensin Receptor Antagonists | 11 | 2023 | 1039 | 2.300 |
Why?
|
| Tetrazoles | 8 | 2023 | 909 | 2.200 |
Why?
|
| Ventricular Function, Left | 23 | 2024 | 3879 | 2.170 |
Why?
|
| Coronary Stenosis | 7 | 2023 | 794 | 2.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 26 | 2024 | 12148 | 2.030 |
Why?
|
| Humans | 545 | 2024 | 761572 | 2.010 |
Why?
|
| Atrial Natriuretic Factor | 13 | 2022 | 350 | 1.990 |
Why?
|
| Neprilysin | 7 | 2020 | 478 | 1.970 |
Why?
|
| Coronary Artery Disease | 23 | 2023 | 6403 | 1.950 |
Why?
|
| Acute Disease | 72 | 2020 | 7237 | 1.880 |
Why?
|
| Predictive Value of Tests | 83 | 2023 | 15266 | 1.870 |
Why?
|
| Proteomics | 9 | 2024 | 3848 | 1.760 |
Why?
|
| Risk Assessment | 70 | 2024 | 23996 | 1.710 |
Why?
|
| Lipoprotein(a) | 6 | 2024 | 480 | 1.700 |
Why?
|
| Aged | 224 | 2024 | 169310 | 1.570 |
Why?
|
| Heart Diseases | 20 | 2021 | 2781 | 1.480 |
Why?
|
| C-Reactive Protein | 18 | 2022 | 3826 | 1.460 |
Why?
|
| Male | 295 | 2024 | 360842 | 1.410 |
Why?
|
| Middle Aged | 237 | 2024 | 220920 | 1.400 |
Why?
|
| Echocardiography | 29 | 2024 | 4989 | 1.400 |
Why?
|
| Cardiology | 16 | 2024 | 1656 | 1.340 |
Why?
|
| Myocardial Ischemia | 13 | 2022 | 2113 | 1.340 |
Why?
|
| Female | 301 | 2024 | 392686 | 1.310 |
Why?
|
| Cardiovascular Agents | 11 | 2024 | 840 | 1.290 |
Why?
|
| Drug Combinations | 10 | 2023 | 2048 | 1.240 |
Why?
|
| Renal Insufficiency | 10 | 2018 | 809 | 1.240 |
Why?
|
| Coronary Disease | 18 | 2018 | 5914 | 1.230 |
Why?
|
| Diuretics | 8 | 2020 | 610 | 1.220 |
Why?
|
| Endothelin-1 | 4 | 2018 | 302 | 1.210 |
Why?
|
| Growth Differentiation Factor 15 | 7 | 2016 | 198 | 1.200 |
Why?
|
| Clinical Trials as Topic | 23 | 2024 | 8002 | 1.180 |
Why?
|
| Adrenergic beta-Antagonists | 10 | 2023 | 1241 | 1.150 |
Why?
|
| Aldehyde Reductase | 2 | 2024 | 71 | 1.130 |
Why?
|
| Disease Management | 11 | 2021 | 2508 | 1.130 |
Why?
|
| Patient Readmission | 16 | 2023 | 3271 | 1.120 |
Why?
|
| Consensus | 12 | 2024 | 3123 | 1.080 |
Why?
|
| Prospective Studies | 82 | 2024 | 54426 | 1.070 |
Why?
|
| Angiography | 5 | 2022 | 1595 | 1.070 |
Why?
|
| Risk Factors | 98 | 2024 | 74213 | 1.060 |
Why?
|
| Anterior Wall Myocardial Infarction | 2 | 2023 | 42 | 1.040 |
Why?
|
| Lipocalins | 5 | 2015 | 161 | 1.030 |
Why?
|
| Severity of Illness Index | 44 | 2022 | 15843 | 0.990 |
Why?
|
| Acute Kidney Injury | 6 | 2022 | 1924 | 0.980 |
Why?
|
| Heart Failure, Diastolic | 3 | 2016 | 76 | 0.980 |
Why?
|
| Emergency Service, Hospital | 32 | 2021 | 7879 | 0.970 |
Why?
|
| Tyrosine | 8 | 2004 | 1440 | 0.960 |
Why?
|
| Outpatients | 6 | 2018 | 1597 | 0.960 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2023 | 2243 | 0.950 |
Why?
|
| Intramolecular Oxidoreductases | 3 | 2013 | 105 | 0.930 |
Why?
|
| Diabetic Nephropathies | 4 | 2024 | 973 | 0.930 |
Why?
|
| Phospholipids | 3 | 2024 | 786 | 0.920 |
Why?
|
| Cardiovascular System | 4 | 2024 | 834 | 0.920 |
Why?
|
| Chronic Disease | 30 | 2022 | 9319 | 0.900 |
Why?
|
| Glucosides | 4 | 2024 | 512 | 0.880 |
Why?
|
| Cystatin C | 5 | 2022 | 270 | 0.880 |
Why?
|
| ROC Curve | 21 | 2020 | 3579 | 0.870 |
Why?
|
| Follow-Up Studies | 54 | 2023 | 39107 | 0.870 |
Why?
|
| Treatment Outcome | 73 | 2024 | 64684 | 0.850 |
Why?
|
| Oxidation-Reduction | 4 | 2024 | 2231 | 0.840 |
Why?
|
| Angiopoietin-2 | 1 | 2023 | 172 | 0.830 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2024 | 3492 | 0.830 |
Why?
|
| Artificial Intelligence | 3 | 2023 | 2578 | 0.820 |
Why?
|
| Disease Progression | 20 | 2024 | 13510 | 0.820 |
Why?
|
| Patient Care Management | 3 | 2020 | 302 | 0.810 |
Why?
|
| Plaque, Atherosclerotic | 5 | 2023 | 1533 | 0.800 |
Why?
|
| Aortic Aneurysm | 11 | 2009 | 648 | 0.790 |
Why?
|
| Angina, Unstable | 8 | 2019 | 888 | 0.780 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 7 | 2022 | 1516 | 0.770 |
Why?
|
| Practice Guidelines as Topic | 15 | 2020 | 7391 | 0.760 |
Why?
|
| Benzhydryl Compounds | 4 | 2024 | 916 | 0.760 |
Why?
|
| Creatinine | 13 | 2023 | 1899 | 0.760 |
Why?
|
| Coronary Artery Bypass | 9 | 2021 | 2188 | 0.750 |
Why?
|
| Cardiac Resynchronization Therapy | 6 | 2020 | 555 | 0.730 |
Why?
|
| Glomerular Filtration Rate | 13 | 2023 | 2177 | 0.730 |
Why?
|
| Panic Disorder | 3 | 2014 | 613 | 0.730 |
Why?
|
| Expert Testimony | 3 | 2020 | 364 | 0.730 |
Why?
|
| Systole | 5 | 2017 | 936 | 0.720 |
Why?
|
| Electrocardiography | 19 | 2019 | 6377 | 0.720 |
Why?
|
| Time Factors | 46 | 2024 | 39970 | 0.720 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2024 | 558 | 0.710 |
Why?
|
| Research Report | 3 | 2020 | 367 | 0.700 |
Why?
|
| Hospitalization | 29 | 2022 | 10721 | 0.690 |
Why?
|
| Pyridazines | 1 | 2022 | 202 | 0.690 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 3 | 2020 | 431 | 0.690 |
Why?
|
| Aged, 80 and over | 70 | 2024 | 58986 | 0.690 |
Why?
|
| Proportional Hazards Models | 23 | 2022 | 12463 | 0.680 |
Why?
|
| Adrenomedullin | 5 | 2017 | 85 | 0.680 |
Why?
|
| Hypertension | 11 | 2023 | 8540 | 0.670 |
Why?
|
| Calcitonin | 3 | 2015 | 329 | 0.670 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2023 | 323 | 0.660 |
Why?
|
| Hyperlipoproteinemias | 1 | 2019 | 20 | 0.660 |
Why?
|
| Baroreflex | 1 | 2020 | 149 | 0.660 |
Why?
|
| Inpatients | 11 | 2014 | 2548 | 0.650 |
Why?
|
| Diagnostic Errors | 2 | 2024 | 1265 | 0.650 |
Why?
|
| Cardiac Output, Low | 3 | 2015 | 191 | 0.650 |
Why?
|
| Depression | 15 | 2017 | 8124 | 0.640 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2022 | 369 | 0.640 |
Why?
|
| Heparin | 9 | 2010 | 1634 | 0.630 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 7 | 2004 | 577 | 0.630 |
Why?
|
| Myocardium | 11 | 2017 | 4725 | 0.610 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 3 | 2020 | 152 | 0.600 |
Why?
|
| Dyslipidemias | 2 | 2022 | 868 | 0.590 |
Why?
|
| Sensitivity and Specificity | 29 | 2021 | 14666 | 0.580 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2022 | 748 | 0.580 |
Why?
|
| Oxygen Consumption | 3 | 2024 | 1866 | 0.580 |
Why?
|
| Manuscripts as Topic | 1 | 2017 | 15 | 0.580 |
Why?
|
| Cardiotonic Agents | 1 | 2020 | 539 | 0.570 |
Why?
|
| Cause of Death | 11 | 2020 | 3683 | 0.560 |
Why?
|
| Registries | 21 | 2019 | 8224 | 0.560 |
Why?
|
| Apolipoproteins | 1 | 2019 | 326 | 0.550 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 686 | 0.550 |
Why?
|
| Peroxidase | 2 | 2017 | 609 | 0.550 |
Why?
|
| Diabetes Complications | 2 | 2022 | 1315 | 0.550 |
Why?
|
| Kidney Function Tests | 7 | 2018 | 679 | 0.550 |
Why?
|
| Diagnosis, Differential | 28 | 2019 | 12975 | 0.550 |
Why?
|
| Inflammation | 10 | 2022 | 10773 | 0.550 |
Why?
|
| Peripheral Arterial Disease | 2 | 2018 | 1273 | 0.540 |
Why?
|
| Furosemide | 1 | 2017 | 170 | 0.540 |
Why?
|
| Spironolactone | 3 | 2021 | 412 | 0.540 |
Why?
|
| Incidence | 22 | 2024 | 21355 | 0.540 |
Why?
|
| Intensive Care Units | 11 | 2017 | 3744 | 0.540 |
Why?
|
| Protease Inhibitors | 1 | 2020 | 754 | 0.540 |
Why?
|
| Kidney | 7 | 2022 | 7047 | 0.540 |
Why?
|
| Athletes | 1 | 2024 | 1137 | 0.540 |
Why?
|
| Neurotensin | 1 | 2016 | 60 | 0.530 |
Why?
|
| Catheterization | 3 | 2018 | 1428 | 0.530 |
Why?
|
| Coronary Vessels | 5 | 2019 | 3096 | 0.520 |
Why?
|
| Renin-Angiotensin System | 2 | 2018 | 737 | 0.510 |
Why?
|
| Imidazoles | 1 | 2022 | 1180 | 0.510 |
Why?
|
| Ventricular Function | 1 | 2017 | 406 | 0.510 |
Why?
|
| Catheters | 1 | 2018 | 427 | 0.510 |
Why?
|
| Glycopeptides | 2 | 2014 | 220 | 0.500 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2015 | 82 | 0.500 |
Why?
|
| Survival Analysis | 22 | 2019 | 10090 | 0.490 |
Why?
|
| Shock | 4 | 2008 | 314 | 0.490 |
Why?
|
| Blood Proteins | 2 | 2018 | 1173 | 0.490 |
Why?
|
| Multivariate Analysis | 24 | 2018 | 12059 | 0.490 |
Why?
|
| Kidney Diseases | 7 | 2022 | 2091 | 0.490 |
Why?
|
| Hypoglycemic Agents | 7 | 2023 | 3085 | 0.490 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2015 | 169 | 0.490 |
Why?
|
| Receptors, Interleukin-1 | 5 | 2018 | 262 | 0.480 |
Why?
|
| Cachexia | 1 | 2016 | 202 | 0.480 |
Why?
|
| United States | 47 | 2024 | 72335 | 0.480 |
Why?
|
| Catheterization, Peripheral | 1 | 2018 | 343 | 0.470 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2017 | 170 | 0.470 |
Why?
|
| Creatine Kinase | 9 | 2014 | 685 | 0.470 |
Why?
|
| Heart Ventricles | 7 | 2019 | 3807 | 0.460 |
Why?
|
| Anxiety Disorders | 6 | 2013 | 2720 | 0.460 |
Why?
|
| Stroke | 10 | 2023 | 9758 | 0.460 |
Why?
|
| Peer Review, Research | 1 | 2017 | 340 | 0.450 |
Why?
|
| Area Under Curve | 7 | 2023 | 1638 | 0.450 |
Why?
|
| Cohort Studies | 41 | 2024 | 41493 | 0.440 |
Why?
|
| Fibrinolytic Agents | 7 | 2018 | 2084 | 0.440 |
Why?
|
| Diabetes Mellitus | 6 | 2023 | 5841 | 0.440 |
Why?
|
| Prevalence | 16 | 2022 | 15732 | 0.420 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 1551 | 0.410 |
Why?
|
| Heart Valve Prosthesis Implantation | 5 | 2024 | 1553 | 0.410 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 1089 | 0.410 |
Why?
|
| Survival Rate | 19 | 2019 | 12725 | 0.400 |
Why?
|
| Heart | 3 | 2021 | 4404 | 0.390 |
Why?
|
| Research | 1 | 2020 | 1982 | 0.390 |
Why?
|
| Serum Albumin | 3 | 2010 | 672 | 0.390 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 161 | 0.390 |
Why?
|
| Lung Diseases | 2 | 2015 | 1909 | 0.390 |
Why?
|
| Cardiac Imaging Techniques | 3 | 2018 | 267 | 0.390 |
Why?
|
| Shock, Cardiogenic | 2 | 2017 | 709 | 0.380 |
Why?
|
| Contrast Media | 5 | 2022 | 5311 | 0.380 |
Why?
|
| Quality of Life | 13 | 2024 | 13367 | 0.370 |
Why?
|
| International Classification of Diseases | 4 | 2021 | 909 | 0.370 |
Why?
|
| Atrial Fibrillation | 7 | 2023 | 5127 | 0.370 |
Why?
|
| Platelet Aggregation Inhibitors | 6 | 2014 | 2751 | 0.370 |
Why?
|
| Aortic Aneurysm, Thoracic | 4 | 2011 | 696 | 0.370 |
Why?
|
| Anxiety | 7 | 2016 | 4573 | 0.360 |
Why?
|
| Aortic Valve Stenosis | 2 | 2024 | 2001 | 0.360 |
Why?
|
| Obesity | 11 | 2023 | 12947 | 0.360 |
Why?
|
| Angina Pectoris | 4 | 2021 | 959 | 0.360 |
Why?
|
| Hospitalists | 1 | 2014 | 294 | 0.360 |
Why?
|
| Sex Factors | 10 | 2020 | 10553 | 0.360 |
Why?
|
| Anticoagulants | 7 | 2019 | 4812 | 0.360 |
Why?
|
| Ambulatory Care | 5 | 2016 | 2775 | 0.350 |
Why?
|
| Angina Pectoris, Variant | 1 | 2010 | 53 | 0.350 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 1809 | 0.350 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2021 | 488 | 0.350 |
Why?
|
| Patient Selection | 4 | 2016 | 4244 | 0.350 |
Why?
|
| Heart Valve Prosthesis | 1 | 2018 | 1462 | 0.340 |
Why?
|
| Exercise Tolerance | 3 | 2024 | 836 | 0.340 |
Why?
|
| Myocardial Contraction | 2 | 2014 | 1515 | 0.340 |
Why?
|
| Antidepressive Agents | 7 | 2013 | 2897 | 0.340 |
Why?
|
| Early Diagnosis | 1 | 2015 | 1186 | 0.340 |
Why?
|
| Tomography, X-Ray Computed | 13 | 2023 | 20571 | 0.340 |
Why?
|
| Comorbidity | 19 | 2024 | 10508 | 0.330 |
Why?
|
| Isoenzymes | 7 | 2007 | 1687 | 0.330 |
Why?
|
| Evidence-Based Medicine | 6 | 2018 | 3688 | 0.330 |
Why?
|
| Ticlopidine | 1 | 2014 | 730 | 0.330 |
Why?
|
| Erythropoietin | 3 | 2009 | 719 | 0.330 |
Why?
|
| Depressive Disorder, Major | 9 | 2010 | 4761 | 0.330 |
Why?
|
| Adenosine | 1 | 2014 | 808 | 0.330 |
Why?
|
| Arrhythmias, Cardiac | 7 | 2014 | 2244 | 0.330 |
Why?
|
| Cardiomyopathies | 4 | 2022 | 1964 | 0.320 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2016 | 6484 | 0.320 |
Why?
|
| Cooperative Behavior | 4 | 2016 | 1505 | 0.320 |
Why?
|
| Body Mass Index | 8 | 2021 | 12954 | 0.320 |
Why?
|
| Odds Ratio | 15 | 2018 | 9646 | 0.320 |
Why?
|
| Osteoprotegerin | 1 | 2009 | 176 | 0.320 |
Why?
|
| Receptors, Interleukin | 1 | 2010 | 243 | 0.320 |
Why?
|
| Hemorrhage | 4 | 2013 | 3424 | 0.320 |
Why?
|
| Endpoint Determination | 6 | 2020 | 590 | 0.310 |
Why?
|
| Age Factors | 15 | 2021 | 18398 | 0.310 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3086 | 0.310 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2024 | 10766 | 0.310 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2013 | 1651 | 0.310 |
Why?
|
| Length of Stay | 6 | 2021 | 6426 | 0.310 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3206 | 0.310 |
Why?
|
| Reproducibility of Results | 16 | 2018 | 20099 | 0.310 |
Why?
|
| Necrosis | 7 | 2017 | 1611 | 0.310 |
Why?
|
| Hypertrophy, Left Ventricular | 4 | 2024 | 851 | 0.310 |
Why?
|
| American Heart Association | 4 | 2023 | 1039 | 0.310 |
Why?
|
| Adult | 65 | 2022 | 221203 | 0.300 |
Why?
|
| Endothelium, Vascular | 3 | 2018 | 4431 | 0.300 |
Why?
|
| Postoperative Complications | 9 | 2019 | 15633 | 0.300 |
Why?
|
| Hyponatremia | 2 | 2010 | 279 | 0.300 |
Why?
|
| Blood Glucose | 3 | 2017 | 6391 | 0.300 |
Why?
|
| Anemia | 4 | 2009 | 1509 | 0.290 |
Why?
|
| Massachusetts | 10 | 2019 | 8830 | 0.290 |
Why?
|
| Hospital Mortality | 12 | 2021 | 5293 | 0.280 |
Why?
|
| Myxoma | 1 | 2007 | 114 | 0.280 |
Why?
|
| Coronary Care Units | 3 | 2018 | 235 | 0.280 |
Why?
|
| Double-Blind Method | 7 | 2024 | 12341 | 0.280 |
Why?
|
| Attitude to Health | 1 | 2015 | 2025 | 0.270 |
Why?
|
| Linear Models | 8 | 2016 | 5872 | 0.270 |
Why?
|
| Retrospective Studies | 31 | 2022 | 80646 | 0.270 |
Why?
|
| Economics, Hospital | 2 | 2019 | 210 | 0.270 |
Why?
|
| Radiography, Thoracic | 3 | 2010 | 1302 | 0.270 |
Why?
|
| Marfan Syndrome | 3 | 2007 | 236 | 0.270 |
Why?
|
| Pandemics | 3 | 2020 | 8656 | 0.260 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2007 | 308 | 0.260 |
Why?
|
| North America | 3 | 2019 | 1276 | 0.260 |
Why?
|
| Brain Ischemia | 2 | 2009 | 3049 | 0.260 |
Why?
|
| Radiation Dosage | 3 | 2018 | 1958 | 0.250 |
Why?
|
| Motor Activity | 1 | 2015 | 2715 | 0.250 |
Why?
|
| Syndrome | 9 | 2014 | 3267 | 0.250 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2022 | 3204 | 0.250 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 5672 | 0.250 |
Why?
|
| Drug Hypersensitivity | 1 | 2014 | 917 | 0.250 |
Why?
|
| Echocardiography, Doppler | 4 | 2019 | 897 | 0.250 |
Why?
|
| Health Status | 8 | 2024 | 4077 | 0.250 |
Why?
|
| Kidney Failure, Chronic | 3 | 2024 | 2472 | 0.240 |
Why?
|
| Analysis of Variance | 4 | 2019 | 6228 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2024 | 10212 | 0.240 |
Why?
|
| Hemoglobins | 2 | 2009 | 1526 | 0.240 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2011 | 3627 | 0.240 |
Why?
|
| Physicians | 3 | 2014 | 4591 | 0.240 |
Why?
|
| Reference Values | 9 | 2019 | 4920 | 0.230 |
Why?
|
| Postoperative Care | 1 | 2011 | 1468 | 0.230 |
Why?
|
| Sepsis | 3 | 2008 | 2585 | 0.230 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2006 | 422 | 0.230 |
Why?
|
| Long QT Syndrome | 3 | 2014 | 467 | 0.230 |
Why?
|
| Embolism | 1 | 2007 | 399 | 0.230 |
Why?
|
| Biomedical Research | 2 | 2017 | 3429 | 0.230 |
Why?
|
| Heart Neoplasms | 1 | 2007 | 362 | 0.230 |
Why?
|
| Depressive Disorder | 3 | 2013 | 3728 | 0.220 |
Why?
|
| Oxygen | 2 | 2017 | 4227 | 0.220 |
Why?
|
| Up-Regulation | 4 | 2018 | 4124 | 0.220 |
Why?
|
| Guideline Adherence | 4 | 2023 | 2220 | 0.220 |
Why?
|
| Confidence Intervals | 6 | 2019 | 2927 | 0.220 |
Why?
|
| Patient Discharge | 7 | 2020 | 3443 | 0.220 |
Why?
|
| Exercise Test | 3 | 2024 | 2127 | 0.220 |
Why?
|
| Angioplasty, Balloon, Coronary | 5 | 2018 | 1725 | 0.210 |
Why?
|
| Sex Characteristics | 2 | 2020 | 2639 | 0.210 |
Why?
|
| Research Design | 3 | 2017 | 6180 | 0.210 |
Why?
|
| Patient Care | 2 | 2018 | 622 | 0.210 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2007 | 710 | 0.200 |
Why?
|
| Drug Therapy | 1 | 2005 | 503 | 0.200 |
Why?
|
| Nerve Tissue Proteins | 2 | 2005 | 4415 | 0.200 |
Why?
|
| Aortic Rupture | 1 | 2005 | 319 | 0.200 |
Why?
|
| Cross-Sectional Studies | 14 | 2019 | 26127 | 0.200 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2022 | 151 | 0.200 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 1902 | 0.200 |
Why?
|
| Atherosclerosis | 4 | 2023 | 3408 | 0.200 |
Why?
|
| Diabetic Angiopathies | 1 | 2007 | 803 | 0.200 |
Why?
|
| Psychiatric Status Rating Scales | 6 | 2013 | 6019 | 0.200 |
Why?
|
| Thrombocytopenia | 2 | 2000 | 1182 | 0.200 |
Why?
|
| Emergency Medical Services | 5 | 2017 | 1923 | 0.190 |
Why?
|
| Recovery of Function | 4 | 2020 | 2979 | 0.190 |
Why?
|
| Myocytes, Cardiac | 3 | 2021 | 1668 | 0.190 |
Why?
|
| Cholesterol, LDL | 3 | 2021 | 2382 | 0.190 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2023 | 416 | 0.190 |
Why?
|
| Chi-Square Distribution | 5 | 2015 | 3416 | 0.190 |
Why?
|
| Censuses | 1 | 2022 | 202 | 0.190 |
Why?
|
| Tachycardia, Ventricular | 1 | 2010 | 1304 | 0.180 |
Why?
|
| Point-of-Care Systems | 5 | 2011 | 1213 | 0.180 |
Why?
|
| Substance-Related Disorders | 2 | 2017 | 4420 | 0.180 |
Why?
|
| Critical Illness | 4 | 2017 | 2723 | 0.180 |
Why?
|
| Interleukin-18 | 1 | 2022 | 250 | 0.180 |
Why?
|
| Relaxin | 1 | 2020 | 42 | 0.180 |
Why?
|
| Ischemic Attack, Transient | 2 | 2016 | 882 | 0.180 |
Why?
|
| Adiponectin | 2 | 2020 | 1113 | 0.180 |
Why?
|
| Risk | 7 | 2016 | 9610 | 0.180 |
Why?
|
| Apolipoprotein A-I | 2 | 2011 | 299 | 0.180 |
Why?
|
| Evolution, Molecular | 1 | 2009 | 1886 | 0.180 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 13642 | 0.180 |
Why?
|
| Erythrocytes | 1 | 2009 | 2413 | 0.180 |
Why?
|
| Osteopontin | 1 | 2022 | 301 | 0.180 |
Why?
|
| Standard of Care | 2 | 2016 | 551 | 0.170 |
Why?
|
| Wind | 1 | 2020 | 42 | 0.170 |
Why?
|
| Hospitals, University | 2 | 2019 | 564 | 0.170 |
Why?
|
| Boston | 8 | 2019 | 9326 | 0.170 |
Why?
|
| Decision Trees | 2 | 2017 | 504 | 0.170 |
Why?
|
| Regression Analysis | 6 | 2016 | 6344 | 0.170 |
Why?
|
| Constriction, Pathologic | 1 | 2023 | 1096 | 0.170 |
Why?
|
| Databases, Factual | 3 | 2021 | 7967 | 0.170 |
Why?
|
| Myocardial Revascularization | 2 | 2018 | 790 | 0.170 |
Why?
|
| Patient Admission | 2 | 2019 | 1367 | 0.170 |
Why?
|
| Graft Rejection | 1 | 2013 | 4446 | 0.170 |
Why?
|
| Bayes Theorem | 2 | 2023 | 2330 | 0.170 |
Why?
|
| Pharmacological Phenomena | 1 | 2019 | 11 | 0.170 |
Why?
|
| Choice Behavior | 1 | 2005 | 824 | 0.170 |
Why?
|
| United States Food and Drug Administration | 4 | 2024 | 1664 | 0.170 |
Why?
|
| Blood Chemical Analysis | 3 | 2015 | 437 | 0.170 |
Why?
|
| Blood Pressure | 6 | 2021 | 8481 | 0.160 |
Why?
|
| Heart Transplantation | 1 | 2013 | 3233 | 0.160 |
Why?
|
| Blood Urea Nitrogen | 3 | 2011 | 186 | 0.160 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2023 | 353 | 0.160 |
Why?
|
| Thrombosis | 4 | 2019 | 2942 | 0.160 |
Why?
|
| Creatine Kinase, MB Form | 6 | 2006 | 202 | 0.160 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2010 | 1092 | 0.160 |
Why?
|
| Hypothermia, Induced | 2 | 2017 | 753 | 0.160 |
Why?
|
| Coronary Sinus | 2 | 2016 | 84 | 0.160 |
Why?
|
| Menopause, Premature | 1 | 2019 | 124 | 0.160 |
Why?
|
| Emergency Medicine | 1 | 2008 | 1198 | 0.150 |
Why?
|
| Meta-Analysis as Topic | 2 | 2013 | 1380 | 0.150 |
Why?
|
| Nutrition Surveys | 2 | 2023 | 1733 | 0.150 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 2273 | 0.150 |
Why?
|
| Football | 1 | 2024 | 503 | 0.150 |
Why?
|
| Running | 3 | 2008 | 488 | 0.150 |
Why?
|
| Statistics as Topic | 4 | 2020 | 2358 | 0.150 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2024 | 518 | 0.150 |
Why?
|
| Critical Care | 3 | 2013 | 2697 | 0.150 |
Why?
|
| Death, Sudden, Cardiac | 4 | 2010 | 1555 | 0.150 |
Why?
|
| Anti-Anxiety Agents | 2 | 2013 | 397 | 0.150 |
Why?
|
| Probability | 6 | 2021 | 2477 | 0.150 |
Why?
|
| Immunoassay | 3 | 2017 | 745 | 0.140 |
Why?
|
| Myocardial Perfusion Imaging | 2 | 2013 | 575 | 0.140 |
Why?
|
| Organizational Innovation | 1 | 2020 | 537 | 0.140 |
Why?
|
| Risk Reduction Behavior | 2 | 2020 | 1112 | 0.140 |
Why?
|
| Principal Component Analysis | 1 | 2020 | 945 | 0.140 |
Why?
|
| Logistic Models | 12 | 2014 | 13255 | 0.140 |
Why?
|
| Heart Injuries | 1 | 2019 | 206 | 0.140 |
Why?
|
| Health Services Misuse | 1 | 2019 | 244 | 0.140 |
Why?
|
| Homeostasis | 1 | 2008 | 3323 | 0.140 |
Why?
|
| Forecasting | 3 | 2013 | 2928 | 0.140 |
Why?
|
| Thrombin | 1 | 1999 | 591 | 0.140 |
Why?
|
| Aortic Valve | 3 | 2024 | 1955 | 0.140 |
Why?
|
| Statistics, Nonparametric | 4 | 2010 | 2850 | 0.140 |
Why?
|
| Hypotension | 3 | 2020 | 879 | 0.130 |
Why?
|
| Angiotensins | 1 | 2017 | 143 | 0.130 |
Why?
|
| Single-Blind Method | 4 | 2017 | 1574 | 0.130 |
Why?
|
| Triage | 2 | 2016 | 986 | 0.130 |
Why?
|
| Drug Labeling | 1 | 2018 | 248 | 0.130 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2022 | 829 | 0.130 |
Why?
|
| Evaluation Studies as Topic | 1 | 2018 | 1624 | 0.130 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 1156 | 0.130 |
Why?
|
| Terminology as Topic | 2 | 2020 | 1530 | 0.130 |
Why?
|
| Drug Monitoring | 2 | 2019 | 962 | 0.130 |
Why?
|
| Inflammation Mediators | 2 | 2017 | 1886 | 0.130 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 3 | 2020 | 148 | 0.130 |
Why?
|
| Calcitonin Gene-Related Peptide | 2 | 2015 | 323 | 0.130 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2020 | 311 | 0.130 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2023 | 1935 | 0.130 |
Why?
|
| Cerebrovascular Trauma | 1 | 2015 | 22 | 0.130 |
Why?
|
| Ventilator Weaning | 1 | 2016 | 164 | 0.120 |
Why?
|
| Albumins | 2 | 2011 | 575 | 0.120 |
Why?
|
| Emotions | 3 | 2017 | 2739 | 0.120 |
Why?
|
| Methamphetamine | 1 | 2017 | 165 | 0.120 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2016 | 1400 | 0.120 |
Why?
|
| Myoglobin | 3 | 2005 | 159 | 0.120 |
Why?
|
| Metabolomics | 2 | 2023 | 1659 | 0.120 |
Why?
|
| Animals | 13 | 2022 | 168467 | 0.120 |
Why?
|
| Autonomic Nervous System | 1 | 2020 | 703 | 0.120 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2017 | 362 | 0.120 |
Why?
|
| Extracellular Matrix | 2 | 2014 | 1726 | 0.120 |
Why?
|
| Acetylglucosaminidase | 1 | 2014 | 66 | 0.120 |
Why?
|
| Mass Screening | 3 | 2010 | 5428 | 0.120 |
Why?
|
| Thrombolytic Therapy | 2 | 2018 | 2064 | 0.120 |
Why?
|
| Torsades de Pointes | 2 | 2013 | 78 | 0.120 |
Why?
|
| Hospital Costs | 1 | 2021 | 947 | 0.120 |
Why?
|
| Patient Care Team | 3 | 2016 | 2521 | 0.120 |
Why?
|
| Societies, Medical | 3 | 2019 | 3905 | 0.120 |
Why?
|
| Medicare | 3 | 2024 | 6770 | 0.120 |
Why?
|
| Health Status Indicators | 1 | 2020 | 970 | 0.120 |
Why?
|
| CA-125 Antigen | 1 | 2017 | 281 | 0.120 |
Why?
|
| Clinical Competence | 2 | 2008 | 4793 | 0.120 |
Why?
|
| Troponin C | 2 | 2011 | 24 | 0.120 |
Why?
|
| Lipoproteins, HDL | 1 | 2019 | 676 | 0.120 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2016 | 305 | 0.120 |
Why?
|
| Risk Adjustment | 1 | 2018 | 600 | 0.120 |
Why?
|
| Mortality | 4 | 2019 | 2901 | 0.120 |
Why?
|
| Pre-Eclampsia | 1 | 2024 | 1231 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2020 | 1139 | 0.120 |
Why?
|
| Postoperative Period | 3 | 2010 | 1814 | 0.120 |
Why?
|
| Stress, Psychological | 3 | 2014 | 4481 | 0.120 |
Why?
|
| Oxidative Stress | 2 | 2018 | 3113 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 3810 | 0.110 |
Why?
|
| Forearm | 1 | 2016 | 427 | 0.110 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2019 | 395 | 0.110 |
Why?
|
| Aspirin | 2 | 2010 | 3133 | 0.110 |
Why?
|
| Defibrillators, Implantable | 2 | 2020 | 1490 | 0.110 |
Why?
|
| Heart Arrest | 2 | 2017 | 1514 | 0.110 |
Why?
|
| Reimbursement, Incentive | 1 | 2019 | 543 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 3889 | 0.110 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 495 | 0.110 |
Why?
|
| Protein C | 2 | 2007 | 133 | 0.110 |
Why?
|
| Primary Health Care | 2 | 2011 | 4686 | 0.110 |
Why?
|
| Patient Compliance | 2 | 2016 | 2690 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2024 | 3713 | 0.110 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2023 | 774 | 0.110 |
Why?
|
| Vietnam | 1 | 2014 | 409 | 0.110 |
Why?
|
| Drug Discovery | 1 | 2021 | 1051 | 0.110 |
Why?
|
| Infection Control | 1 | 2020 | 982 | 0.110 |
Why?
|
| Limit of Detection | 1 | 2014 | 273 | 0.110 |
Why?
|
| Apolipoproteins C | 1 | 1992 | 59 | 0.110 |
Why?
|
| Health Behavior | 2 | 2017 | 2644 | 0.110 |
Why?
|
| Blood Specimen Collection | 1 | 2014 | 238 | 0.110 |
Why?
|
| Cholesterol | 1 | 2022 | 2904 | 0.100 |
Why?
|
| Pulmonary Embolism | 1 | 2006 | 2567 | 0.100 |
Why?
|
| Congresses as Topic | 1 | 2018 | 803 | 0.100 |
Why?
|
| Cyanides | 1 | 2013 | 82 | 0.100 |
Why?
|
| Riboflavin | 1 | 2013 | 107 | 0.100 |
Why?
|
| Feasibility Studies | 5 | 2017 | 5247 | 0.100 |
Why?
|
| Anthracyclines | 2 | 2012 | 284 | 0.100 |
Why?
|
| Case-Control Studies | 9 | 2019 | 22176 | 0.100 |
Why?
|
| Pneumonia, Bacterial | 1 | 2015 | 317 | 0.100 |
Why?
|
| Vasodilator Agents | 1 | 2016 | 973 | 0.100 |
Why?
|
| Antidotes | 1 | 2013 | 138 | 0.100 |
Why?
|
| Diastole | 2 | 2012 | 782 | 0.100 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2014 | 432 | 0.100 |
Why?
|
| Electroconvulsive Therapy | 3 | 2011 | 500 | 0.100 |
Why?
|
| Mass Spectrometry | 1 | 2019 | 2192 | 0.100 |
Why?
|
| Losartan | 1 | 2013 | 265 | 0.100 |
Why?
|
| Diffusion of Innovation | 1 | 2017 | 728 | 0.100 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2008 | 628 | 0.100 |
Why?
|
| Phenotype | 2 | 2023 | 16592 | 0.100 |
Why?
|
| Ultrasonography | 4 | 2012 | 5972 | 0.100 |
Why?
|
| Digoxin | 1 | 2012 | 246 | 0.100 |
Why?
|
| Critical Pathways | 2 | 2018 | 474 | 0.100 |
Why?
|
| Sodium-Glucose Transporter 2 | 2 | 2023 | 89 | 0.090 |
Why?
|
| Saphenous Vein | 1 | 2014 | 516 | 0.090 |
Why?
|
| Physical Examination | 3 | 2008 | 1255 | 0.090 |
Why?
|
| Social Work, Psychiatric | 1 | 2011 | 23 | 0.090 |
Why?
|
| Arginine Vasopressin | 1 | 2011 | 125 | 0.090 |
Why?
|
| Algorithms | 6 | 2024 | 14032 | 0.090 |
Why?
|
| Fibrinogen | 1 | 2014 | 888 | 0.090 |
Why?
|
| Osmolar Concentration | 2 | 2009 | 659 | 0.090 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2013 | 1068 | 0.090 |
Why?
|
| Smoking | 3 | 2021 | 9053 | 0.090 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2014 | 537 | 0.090 |
Why?
|
| Coronary Circulation | 1 | 2017 | 1569 | 0.090 |
Why?
|
| Child of Impaired Parents | 1 | 2014 | 460 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 4 | 2016 | 5492 | 0.090 |
Why?
|
| Pain Measurement | 1 | 2001 | 3551 | 0.090 |
Why?
|
| Patient Care Planning | 1 | 2016 | 909 | 0.090 |
Why?
|
| Austria | 1 | 2011 | 207 | 0.090 |
Why?
|
| Galectins | 1 | 2013 | 295 | 0.090 |
Why?
|
| Cardiac Tamponade | 2 | 2009 | 175 | 0.090 |
Why?
|
| Fibrosis | 3 | 2022 | 2049 | 0.090 |
Why?
|
| Catheter Ablation | 1 | 2023 | 2751 | 0.090 |
Why?
|
| Magnesium | 2 | 2010 | 804 | 0.090 |
Why?
|
| Haloperidol | 1 | 2011 | 389 | 0.090 |
Why?
|
| Europe | 4 | 2020 | 3422 | 0.080 |
Why?
|
| Personality Inventory | 2 | 2010 | 1019 | 0.080 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2011 | 393 | 0.080 |
Why?
|
| Rest | 1 | 2014 | 918 | 0.080 |
Why?
|
| Glycoproteins | 1 | 2017 | 2203 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 1135 | 0.080 |
Why?
|
| Laboratories, Hospital | 1 | 2011 | 192 | 0.080 |
Why?
|
| Heart-Assist Devices | 1 | 2020 | 1287 | 0.080 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2011 | 296 | 0.080 |
Why?
|
| Spain | 1 | 2011 | 487 | 0.080 |
Why?
|
| Longitudinal Studies | 5 | 2023 | 14607 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 3245 | 0.080 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2009 | 65 | 0.080 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2007 | 1086 | 0.080 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 1670 | 0.080 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2009 | 117 | 0.080 |
Why?
|
| Perioperative Care | 1 | 2017 | 1036 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2024 | 857 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2020 | 1852 | 0.080 |
Why?
|
| Epidemiologic Methods | 3 | 2008 | 1336 | 0.080 |
Why?
|
| Antipsychotic Agents | 2 | 2013 | 3067 | 0.080 |
Why?
|
| Heparitin Sulfate | 2 | 2000 | 223 | 0.080 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2011 | 459 | 0.080 |
Why?
|
| Atrial Function, Left | 1 | 2010 | 185 | 0.080 |
Why?
|
| Insulin | 1 | 2023 | 6597 | 0.080 |
Why?
|
| Insurance, Health | 1 | 2021 | 2498 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 1792 | 0.080 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 1924 | 0.080 |
Why?
|
| Medical Records | 3 | 2006 | 1408 | 0.080 |
Why?
|
| Sex Distribution | 4 | 2009 | 2281 | 0.080 |
Why?
|
| Solubility | 3 | 2016 | 1091 | 0.070 |
Why?
|
| Occupational Exposure | 1 | 2018 | 1813 | 0.070 |
Why?
|
| Norway | 1 | 2009 | 499 | 0.070 |
Why?
|
| Cell Size | 1 | 2009 | 624 | 0.070 |
Why?
|
| Bronchial Arteries | 1 | 2007 | 21 | 0.070 |
Why?
|
| New York | 1 | 2010 | 874 | 0.070 |
Why?
|
| Emergencies | 2 | 2006 | 1217 | 0.070 |
Why?
|
| Benchmarking | 3 | 2018 | 1045 | 0.070 |
Why?
|
| Neurotransmitter Agents | 1 | 2011 | 665 | 0.070 |
Why?
|
| Lipoproteins, LDL | 1 | 2011 | 642 | 0.070 |
Why?
|
| Diagnostic Tests, Routine | 3 | 2013 | 787 | 0.070 |
Why?
|
| Stents | 3 | 2014 | 3179 | 0.070 |
Why?
|
| Recurrence | 5 | 2008 | 8466 | 0.070 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2007 | 96 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2013 | 11742 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 2421 | 0.070 |
Why?
|
| Health Care Costs | 2 | 2021 | 3242 | 0.070 |
Why?
|
| Heart Rate | 2 | 2011 | 4195 | 0.070 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 2007 | 92 | 0.070 |
Why?
|
| Hemodynamics | 2 | 2014 | 4160 | 0.070 |
Why?
|
| Asthma | 1 | 2006 | 6234 | 0.070 |
Why?
|
| Denmark | 1 | 2009 | 771 | 0.070 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 1667 | 0.070 |
Why?
|
| Embolectomy | 1 | 2007 | 129 | 0.070 |
Why?
|
| Psychotherapy | 2 | 2013 | 1647 | 0.070 |
Why?
|
| Age Distribution | 3 | 2015 | 2880 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2016 | 3208 | 0.070 |
Why?
|
| Myocardial Stunning | 1 | 2006 | 66 | 0.070 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2008 | 123 | 0.070 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2007 | 277 | 0.070 |
Why?
|
| Paresis | 1 | 2007 | 176 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2013 | 8633 | 0.070 |
Why?
|
| Behavior Therapy | 1 | 2012 | 879 | 0.070 |
Why?
|
| Diagnostic Imaging | 2 | 2018 | 3530 | 0.070 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2008 | 513 | 0.070 |
Why?
|
| Radiographic Image Enhancement | 1 | 2011 | 876 | 0.070 |
Why?
|
| Fibrinolysis | 1 | 2007 | 332 | 0.070 |
Why?
|
| Delirium | 1 | 2018 | 1668 | 0.070 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2007 | 239 | 0.070 |
Why?
|
| General Surgery | 1 | 2017 | 1692 | 0.060 |
Why?
|
| Coronary Occlusion | 1 | 2009 | 304 | 0.060 |
Why?
|
| Hematinics | 1 | 2009 | 282 | 0.060 |
Why?
|
| Heart Murmurs | 1 | 2006 | 92 | 0.060 |
Why?
|
| Pain | 1 | 2001 | 5073 | 0.060 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2019 | 1050 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2015 | 4513 | 0.060 |
Why?
|
| Medicaid | 1 | 2019 | 2818 | 0.060 |
Why?
|
| Young Adult | 5 | 2022 | 59255 | 0.060 |
Why?
|
| Mental Health | 2 | 2017 | 3250 | 0.060 |
Why?
|
| Anesthesia, Spinal | 1 | 2008 | 280 | 0.060 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2004 | 20 | 0.060 |
Why?
|
| Vascular Surgical Procedures | 2 | 2011 | 1489 | 0.060 |
Why?
|
| Interleukins | 1 | 2010 | 782 | 0.060 |
Why?
|
| Radiography | 4 | 2009 | 6965 | 0.060 |
Why?
|
| Weight Loss | 1 | 2016 | 2684 | 0.060 |
Why?
|
| Referral and Consultation | 1 | 2018 | 3600 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2024 | 1702 | 0.060 |
Why?
|
| Syncope | 1 | 2007 | 427 | 0.060 |
Why?
|
| Suicidal Ideation | 1 | 2014 | 1447 | 0.060 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2008 | 481 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 2898 | 0.060 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2013 | 1310 | 0.060 |
Why?
|
| Chromosome Mapping | 1 | 1992 | 4615 | 0.060 |
Why?
|
| Biological Assay | 1 | 2007 | 626 | 0.060 |
Why?
|
| Transplantation, Homologous | 1 | 2013 | 4807 | 0.060 |
Why?
|
| Hyperglycemia | 1 | 2013 | 1376 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 2012 | 13446 | 0.060 |
Why?
|
| Blood Coagulation Disorders | 1 | 2007 | 350 | 0.060 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2024 | 66 | 0.060 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2004 | 86 | 0.060 |
Why?
|
| Models, Biological | 1 | 2020 | 9469 | 0.060 |
Why?
|
| Iatrogenic Disease | 2 | 2009 | 539 | 0.060 |
Why?
|
| Membrane Glycoproteins | 1 | 2014 | 3701 | 0.060 |
Why?
|
| Acute-Phase Proteins | 2 | 2015 | 250 | 0.060 |
Why?
|
| Apoprotein(a) | 1 | 2023 | 17 | 0.060 |
Why?
|
| Preoperative Period | 2 | 2019 | 551 | 0.050 |
Why?
|
| Neointima | 2 | 2014 | 133 | 0.050 |
Why?
|
| Molecular Weight | 1 | 2006 | 2186 | 0.050 |
Why?
|
| Patient Education as Topic | 2 | 2011 | 2319 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2018 | 4330 | 0.050 |
Why?
|
| Fibroblast Growth Factors | 1 | 2009 | 867 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 2020 | 6534 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 2012 | 17635 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2016 | 3537 | 0.050 |
Why?
|
| Apolipoproteins A | 1 | 2023 | 95 | 0.050 |
Why?
|
| Balloon Occlusion | 1 | 2003 | 125 | 0.050 |
Why?
|
| Bundle-Branch Block | 2 | 2017 | 276 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2011 | 1974 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2007 | 1835 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2003 | 231 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 2024 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2001 | 6312 | 0.050 |
Why?
|
| Apoptosis | 1 | 2018 | 9489 | 0.050 |
Why?
|
| Physical Fitness | 1 | 2006 | 743 | 0.050 |
Why?
|
| Judgment | 1 | 2004 | 273 | 0.050 |
Why?
|
| Radial Artery | 1 | 2003 | 187 | 0.050 |
Why?
|
| Mitral Valve | 1 | 2010 | 1465 | 0.050 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2003 | 445 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 2 | 2013 | 2691 | 0.050 |
Why?
|
| Apolipoproteins B | 1 | 2023 | 386 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2015 | 3980 | 0.050 |
Why?
|
| Rare Diseases | 1 | 2006 | 622 | 0.050 |
Why?
|
| Tomography, Optical Coherence | 1 | 2014 | 2917 | 0.050 |
Why?
|
| Aorta, Thoracic | 1 | 2007 | 1096 | 0.050 |
Why?
|
| Committee Membership | 1 | 2020 | 17 | 0.050 |
Why?
|
| APACHE | 2 | 2013 | 267 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 9177 | 0.050 |
Why?
|
| Hematoma | 1 | 2005 | 767 | 0.050 |
Why?
|
| New England | 1 | 2024 | 1054 | 0.050 |
Why?
|
| Echocardiography, Stress | 1 | 2021 | 134 | 0.050 |
Why?
|
| Telemedicine | 2 | 2017 | 3052 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2006 | 1440 | 0.040 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2003 | 451 | 0.040 |
Why?
|
| Microspheres | 1 | 2003 | 784 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2023 | 306 | 0.040 |
Why?
|
| Platelet Factor 4 | 1 | 2000 | 129 | 0.040 |
Why?
|
| Calcinosis | 1 | 2009 | 1469 | 0.040 |
Why?
|
| Tricuspid Valve | 1 | 2023 | 410 | 0.040 |
Why?
|
| Blood Donors | 1 | 2002 | 345 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2012 | 2176 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2002 | 1379 | 0.040 |
Why?
|
| Ancrod | 1 | 1999 | 7 | 0.040 |
Why?
|
| Hirudin Therapy | 1 | 1999 | 43 | 0.040 |
Why?
|
| Dermatan Sulfate | 1 | 1999 | 43 | 0.040 |
Why?
|
| Taxoids | 2 | 2013 | 668 | 0.040 |
Why?
|
| Product Labeling | 1 | 2020 | 76 | 0.040 |
Why?
|
| Cesarean Section | 1 | 2008 | 1398 | 0.040 |
Why?
|
| Morbidity | 2 | 2019 | 1750 | 0.040 |
Why?
|
| Gangrene | 1 | 1999 | 91 | 0.040 |
Why?
|
| Mental Health Services | 1 | 2011 | 1730 | 0.040 |
Why?
|
| Relaxation Therapy | 1 | 2000 | 181 | 0.040 |
Why?
|
| Chondroitin Sulfates | 1 | 1999 | 174 | 0.040 |
Why?
|
| Pipecolic Acids | 1 | 1999 | 77 | 0.040 |
Why?
|
| Observer Variation | 1 | 2005 | 2606 | 0.040 |
Why?
|
| Albuminuria | 1 | 2022 | 657 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2000 | 817 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2008 | 1796 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2004 | 1596 | 0.040 |
Why?
|
| North Carolina | 1 | 2019 | 325 | 0.040 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2008 | 1228 | 0.040 |
Why?
|
| Fluorocarbons | 1 | 2003 | 492 | 0.040 |
Why?
|
| Plasma Volume | 1 | 2017 | 31 | 0.040 |
Why?
|
| Hirudins | 1 | 1999 | 179 | 0.040 |
Why?
|
| Safety | 1 | 2003 | 1150 | 0.040 |
Why?
|
| Edema, Cardiac | 1 | 2017 | 19 | 0.040 |
Why?
|
| Interdisciplinary Communication | 2 | 2016 | 931 | 0.040 |
Why?
|
| District of Columbia | 1 | 2018 | 159 | 0.040 |
Why?
|
| Cystic Fibrosis | 1 | 2007 | 1285 | 0.040 |
Why?
|
| International Cooperation | 1 | 2004 | 1422 | 0.040 |
Why?
|
| Thrombophilia | 1 | 2000 | 305 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2000 | 662 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 1992 | 12794 | 0.040 |
Why?
|
| Ceruloplasmin | 1 | 2017 | 56 | 0.040 |
Why?
|
| Electric Countershock | 1 | 2020 | 533 | 0.040 |
Why?
|
| Ovariectomy | 1 | 2019 | 614 | 0.040 |
Why?
|
| Myocardial Reperfusion | 1 | 2018 | 338 | 0.040 |
Why?
|
| Streptococcal Infections | 1 | 1981 | 617 | 0.040 |
Why?
|
| Platelet Activation | 1 | 2000 | 645 | 0.040 |
Why?
|
| Breast Neoplasms | 3 | 2013 | 21017 | 0.030 |
Why?
|
| Tissue Survival | 1 | 2017 | 119 | 0.030 |
Why?
|
| Clinical Coding | 1 | 2018 | 181 | 0.030 |
Why?
|
| Hypolipidemic Agents | 1 | 2021 | 609 | 0.030 |
Why?
|
| Cost Savings | 2 | 2016 | 913 | 0.030 |
Why?
|
| Forced Expiratory Volume | 1 | 2022 | 1814 | 0.030 |
Why?
|
| Water-Electrolyte Balance | 1 | 2017 | 325 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 15936 | 0.030 |
Why?
|
| Ventricular Dysfunction | 1 | 2017 | 144 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2021 | 787 | 0.030 |
Why?
|
| Athletic Injuries | 1 | 2006 | 1216 | 0.030 |
Why?
|
| Italy | 1 | 2018 | 842 | 0.030 |
Why?
|
| Haptoglobins | 1 | 2017 | 166 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2020 | 709 | 0.030 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 7827 | 0.030 |
Why?
|
| Platelet Aggregation | 1 | 1999 | 771 | 0.030 |
Why?
|
| Vascular Diseases | 1 | 2024 | 1161 | 0.030 |
Why?
|
| Netherlands | 1 | 2020 | 2221 | 0.030 |
Why?
|
| Arginine | 1 | 1999 | 934 | 0.030 |
Why?
|
| Antithrombins | 1 | 2018 | 294 | 0.030 |
Why?
|
| Internationality | 2 | 2013 | 1001 | 0.030 |
Why?
|
| Hospitals | 2 | 2019 | 3882 | 0.030 |
Why?
|
| Brain | 2 | 2015 | 27120 | 0.030 |
Why?
|
| Pulmonary Edema | 1 | 2017 | 409 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2019 | 771 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2010 | 3763 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2000 | 1560 | 0.030 |
Why?
|
| Vena Cava, Inferior | 1 | 2017 | 458 | 0.030 |
Why?
|
| Furin | 1 | 2014 | 46 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2017 | 916 | 0.030 |
Why?
|
| Bipolar Disorder | 1 | 2011 | 5092 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 1 | 2019 | 751 | 0.030 |
Why?
|
| Epitopes | 1 | 2000 | 2503 | 0.030 |
Why?
|
| Vascular Patency | 2 | 2007 | 911 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2000 | 1492 | 0.030 |
Why?
|
| Overweight | 1 | 2005 | 2417 | 0.030 |
Why?
|
| Telephone | 1 | 2017 | 627 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2017 | 1126 | 0.030 |
Why?
|
| Aging | 1 | 2012 | 8711 | 0.030 |
Why?
|
| Exercise | 1 | 2010 | 5890 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2003 | 2885 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2019 | 1188 | 0.030 |
Why?
|
| Nitroprusside | 1 | 2013 | 272 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2013 | 223 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2016 | 992 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2015 | 462 | 0.030 |
Why?
|
| Pyridones | 1 | 2018 | 809 | 0.030 |
Why?
|
| Physical Exertion | 2 | 2008 | 667 | 0.030 |
Why?
|
| Diet | 1 | 2010 | 8075 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 2016 | 579 | 0.030 |
Why?
|
| Inosine | 1 | 2013 | 130 | 0.030 |
Why?
|
| Germany | 1 | 2014 | 875 | 0.020 |
Why?
|
| Restriction Mapping | 1 | 1992 | 851 | 0.020 |
Why?
|
| Video Games | 1 | 2014 | 198 | 0.020 |
Why?
|
| Combined Modality Therapy | 3 | 2011 | 8528 | 0.020 |
Why?
|
| Dizziness | 1 | 2014 | 259 | 0.020 |
Why?
|
| Models, Economic | 1 | 2016 | 716 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 588 | 0.020 |
Why?
|
| Menopause | 1 | 2019 | 1646 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1992 | 1058 | 0.020 |
Why?
|
| Aftercare | 1 | 2017 | 914 | 0.020 |
Why?
|
| Peptides | 1 | 2003 | 4358 | 0.020 |
Why?
|
| Glycosylation | 1 | 2014 | 1097 | 0.020 |
Why?
|
| Apolipoprotein C-III | 1 | 1992 | 211 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2017 | 2644 | 0.020 |
Why?
|
| Receptors, Virus | 1 | 2014 | 640 | 0.020 |
Why?
|
| Neoplasms | 1 | 2020 | 22173 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2014 | 1152 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2017 | 912 | 0.020 |
Why?
|
| Patient Preference | 1 | 2018 | 924 | 0.020 |
Why?
|
| Warfarin | 1 | 1999 | 1483 | 0.020 |
Why?
|
| Bile Acids and Salts | 1 | 2013 | 393 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2019 | 2495 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 1741 | 0.020 |
Why?
|
| Veins | 1 | 2014 | 768 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2014 | 757 | 0.020 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2008 | 1988 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2020 | 2644 | 0.020 |
Why?
|
| Propensity Score | 1 | 2017 | 1913 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 1981 | 2538 | 0.020 |
Why?
|
| Health Resources | 1 | 2016 | 935 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2010 | 510 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2017 | 4021 | 0.020 |
Why?
|
| Sulfonamides | 1 | 1999 | 1978 | 0.020 |
Why?
|
| Renal Plasma Flow | 1 | 2009 | 27 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2014 | 1023 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2016 | 1722 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2013 | 1682 | 0.020 |
Why?
|
| Pregnancy | 3 | 2024 | 29876 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1992 | 2264 | 0.020 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2011 | 578 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1992 | 2748 | 0.020 |
Why?
|
| Species Specificity | 1 | 1992 | 2414 | 0.020 |
Why?
|
| Quinolones | 1 | 2011 | 378 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2012 | 1596 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 1334 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2018 | 2009 | 0.020 |
Why?
|
| Weight Gain | 1 | 2017 | 2348 | 0.020 |
Why?
|
| Renal Artery | 1 | 2009 | 351 | 0.020 |
Why?
|
| Liver Failure, Acute | 1 | 2009 | 181 | 0.020 |
Why?
|
| Carotid Stenosis | 1 | 2014 | 860 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2013 | 2224 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2013 | 1432 | 0.020 |
Why?
|
| Acidosis, Lactic | 1 | 2008 | 146 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2010 | 1162 | 0.020 |
Why?
|
| Heart Block | 1 | 2008 | 386 | 0.020 |
Why?
|
| Rabbits | 1 | 2013 | 4772 | 0.020 |
Why?
|
| Decision Making | 1 | 2019 | 3929 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 4853 | 0.020 |
Why?
|
| Phosphates | 1 | 2009 | 770 | 0.020 |
Why?
|
| Reference Standards | 1 | 2009 | 1003 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2007 | 561 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2008 | 23447 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 1992 | 2112 | 0.020 |
Why?
|
| Resuscitation | 1 | 2010 | 673 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 36429 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9280 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 12690 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2004 | 6845 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2020 | 10448 | 0.010 |
Why?
|
| Medical History Taking | 1 | 2008 | 774 | 0.010 |
Why?
|
| Life Tables | 1 | 2004 | 364 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1981 | 6346 | 0.010 |
Why?
|
| Adolescent | 2 | 2003 | 88324 | 0.010 |
Why?
|
| Sample Size | 1 | 2007 | 841 | 0.010 |
Why?
|
| Respiratory Tract Diseases | 1 | 2009 | 750 | 0.010 |
Why?
|
| National Health Programs | 1 | 2007 | 440 | 0.010 |
Why?
|
| Suicide | 1 | 2014 | 1601 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 2006 | 341 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2011 | 5035 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2006 | 632 | 0.010 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2009 | 807 | 0.010 |
Why?
|
| Lactic Acid | 1 | 2008 | 1139 | 0.010 |
Why?
|
| Sodium | 1 | 2008 | 1588 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 2006 | 823 | 0.010 |
Why?
|
| Case Management | 1 | 2004 | 272 | 0.010 |
Why?
|
| Data Collection | 1 | 2011 | 3322 | 0.010 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2003 | 352 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 2629 | 0.010 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2009 | 1116 | 0.010 |
Why?
|
| Gene Expression | 1 | 2015 | 7581 | 0.010 |
Why?
|
| Alcohol-Related Disorders | 1 | 2004 | 238 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2004 | 957 | 0.010 |
Why?
|
| Canada | 1 | 2007 | 2122 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 2010 | 1927 | 0.010 |
Why?
|
| Base Sequence | 1 | 1992 | 12441 | 0.010 |
Why?
|
| Coitus | 1 | 2002 | 132 | 0.010 |
Why?
|
| Zebrafish | 1 | 2013 | 3007 | 0.010 |
Why?
|
| Rupture, Spontaneous | 1 | 2002 | 362 | 0.010 |
Why?
|
| Fatigue | 1 | 2008 | 1552 | 0.010 |
Why?
|
| Piperazines | 1 | 2011 | 2523 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2000 | 297 | 0.010 |
Why?
|
| Hospitals, General | 1 | 2004 | 798 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2009 | 1881 | 0.010 |
Why?
|
| Psychometrics | 1 | 2010 | 3065 | 0.010 |
Why?
|
| Consciousness Disorders | 1 | 2004 | 441 | 0.010 |
Why?
|
| Anesthesia | 1 | 2010 | 1595 | 0.010 |
Why?
|
| Coronary Thrombosis | 1 | 2002 | 440 | 0.010 |
Why?
|
| Lung | 1 | 2017 | 10002 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2000 | 522 | 0.010 |
Why?
|
| DNA | 1 | 1992 | 7213 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1992 | 7593 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2009 | 6815 | 0.010 |
Why?
|
| Glycosaminoglycans | 1 | 2000 | 607 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2000 | 803 | 0.010 |
Why?
|
| Embolization, Therapeutic | 1 | 2006 | 1418 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 2006 | 1998 | 0.010 |
Why?
|
| Vitamin D | 1 | 2009 | 3303 | 0.010 |
Why?
|
| Calcium | 1 | 2008 | 5722 | 0.010 |
Why?
|
| Health Expenditures | 1 | 2007 | 2366 | 0.010 |
Why?
|
| Cattle | 1 | 2000 | 3849 | 0.010 |
Why?
|
| Cell Division | 1 | 2000 | 4465 | 0.010 |
Why?
|
| Aorta | 1 | 2000 | 2041 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2003 | 9002 | 0.000 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2004 | 4575 | 0.000 |
Why?
|
| Mice | 1 | 1992 | 81533 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 2000 | 18965 | 0.000 |
Why?
|